Figures & data
Table 1 Characteristics Of The COPD Patients Divided In The Subgroups With Respect To Benefit And Appropriateness Of ICS Therapy In COPD
Figure 1 (A) COPD treatment as percentages of patients in the different COPD treatment groups for all study patients (n = 561). (B) Percentages of patients by severity of airflow limitation and by COPD treatment for all study patients (n = 561).
![Figure 1 (A) COPD treatment as percentages of patients in the different COPD treatment groups for all study patients (n = 561). (B) Percentages of patients by severity of airflow limitation and by COPD treatment for all study patients (n = 561).](/cms/asset/1cbb532f-de70-49b3-b767-bf17a771a696/dcop_a_218747_f0001_b.jpg)
Figure 2 Flow chart of categorizing the COPD patients (n = 561) into subgroups based on comorbidity of asthma, history of exacerbations, B-Eos count and treatment of ICS.
![Figure 2 Flow chart of categorizing the COPD patients (n = 561) into subgroups based on comorbidity of asthma, history of exacerbations, B-Eos count and treatment of ICS.](/cms/asset/17c1ac9f-08f0-494a-b12a-34071ff514c9/dcop_a_218747_f0002_c.jpg)
Figure 3 Adjusted odds ratios with 95% CIs for variables associated with COPD treatment including ICS in combination with LABA and/or LAMA in a multivariable logistic regression analysis, adjusted for sex, study centre and smoking.
![Figure 3 Adjusted odds ratios with 95% CIs for variables associated with COPD treatment including ICS in combination with LABA and/or LAMA in a multivariable logistic regression analysis, adjusted for sex, study centre and smoking.](/cms/asset/da948fbc-4319-4ea7-9fbc-89658155c638/dcop_a_218747_f0003_b.jpg)
Data Availability
Data cannot be made freely available as they are subject to secrecy in accordance with the Swedish Public Access to Information and Secrecy Act, but can be made available to researchers upon request (subject to a review of secrecy).